Publications by authors named "Begona De Miguel Lavisier"
Article Synopsis
- - Spain introduced universal RSV prophylaxis in the 2023-2024 season, allowing all newborns to receive nirsevimab, particularly benefiting infants under 6 months through extended immunization efforts.
- - A study in 15 pediatric emergency departments showed significant decreases in respiratory infections: a 57.7% drop in lower respiratory tract infections and a 63.1% reduction in hospital and PICU admissions related to acute bronchiolitis.
- - The findings indicate that nirsevimab is highly effective in protecting infants from RSV, with extended catch-up immunization yielding the best results, although cost-effectiveness remains a consideration.
Impact of nirsevimab immunization on RSV infections attended in the pediatric emergency department: First results in a tertiary hospital in Madrid.
Enferm Infecc Microbiol Clin (Engl Ed)
August 2024
Article Synopsis
- Human respiratory syncytial virus (RSV) is a leading cause of respiratory infections, and the immunization campaign with the monoclonal antibody nirsevimab started in October 2023.
- A study at a Pediatric Emergency Department in Madrid analyzed RSV infection cases among children eligible for nirsevimab immunization during specific weeks in 2022 and 2023.
- Results showed a significant drop in emergency visits for RSV in 2023 compared to 2022, indicating that nirsevimab effectively reduced RSV-related consultations during the epidemic season.
Background: Although respiratory symptoms are the most prominent manifestations of coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and especially the omicron variant, may cause neurological manifestations such as seizures. It remains unclear if specific variants of the virus increase the risk of seizures more than others.
Material And Methods: This was a retrospective multicenter study of pediatric (zero to 16 years) patients with COVID-19 who attended five pediatric emergency departments in Madrid, Spain, between March 2020 and July 2022.
Objective: Ketamine is a safe and widely used sedative and analgesic in children. The purpose of this study is to evaluate the response to sedoanalgesia for painful procedures in the pediatric emergency department.
Methods: A retrospective study was conducted in children younger than 16 years who underwent painful procedures with intravenous/intranasal ketamine between January 2016 and December 2022.
Introduction: SARS-CoV-2, coronavirus that causes coronavirus disease 2019 (COVID-19), was first detected in Spain on 31 January 2020. On 14 March 2020, a state of emergency was declared in Spain in a bid to control the spread of the COVID-19 pandemic in the country. The aim of our study is to analyze the impact on emergency medicine attendance after the national lockdown, as well as the clinical presentation and the management of patients with suspected COVID-19 in the Paediatric Emergency Department.
View Article and Find Full Text PDFIntroduction: SARS-CoV-2, coronavirus that causes coronavirus disease 2019 (COVID-19), was first detected in Spain on 31 January 2020. On 14 March 2020, a state of emergency was declared in Spain in a bid to control the spread of the COVID-19 pandemic in the country. The aim of our study is to analyse the impact on emergency medicine attendance after the national lockdown, as well as the clinical presentation and the management of patients with suspected COVID-19 in the Paediatric Emergency Department.
View Article and Find Full Text PDF